Dulfer, S. E.
Lange, F.
Sahinovic, M. M.
Wapstra, F. H.
Absalom, A. R.
Faber, C.
Groen, R. J.M.
Drost, G.
Article History
Received: 2 November 2022
Revised: 8 December 2022
Accepted: 31 December 2022
First Online: 13 January 2023
Declarations
:
: ARA reports receipt of unrestricted research funding and/or reimbursement for consultancy for The Medicines Company, Janssen Pharma, Carefusion/BD, Orion Pharma, Ever Pharma, Terumo, PAION and Philips (all for work unrelated to the current study; all payments to institution).The other authors report no conflicts of interest.
: This study will be conducted in accordance with the Declaration of Helsinki and in compliance with the Medical Research Involving Human Subjects Act. Since the data analyzed in this study were collected during routine clinical care, the ethical committee of University Medical Center Groningen (UMCG) waived the requirement for full ethical committee review in accordance with the terms of the Dutch Act on Medical Research on Human Subjects (Wet Medisch-Wetenschappelijk Onderzoek, or ‘WMO’).